Literature DB >> 6577995

HLA and ABO antigens in malignant choroidal melanoma.

H J Völker-Dieben, J D'Amaro, P de Lange, D W Rouendaal.   

Abstract

Comparisons of the HLA antigen frequencies in normal controls and in different subsets of patients with malignant choroidal melanoma, partitioned on the basis of histological tumour cell types and inclusion of the splits of all the HLA-A and -B locus antigens, revealed significant heterogenity only in HLA-B (P = 0.043) in the 'pure spindle' cell type choroidal melanomas. In the 'not pure spindle' cell type choroidal melanomas, borderline heterogenity in HLA-B (P = 0.064) was observed. A comparison of the HLA antigen frequencies in the 'pure' and 'not pure spindle' cell choroidal melanoma patients revealed only one antigen with a significant difference before correction, namely B27. A significant difference in ABO bloodgroup distributions, divided into O and non-O, in the two tumour classes was observed (Exact P(1) = 0.0036).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6577995      PMCID: PMC1535643     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  The use of the 32P test in the management of malignant melanoma of the choroid: a five-year follow-up study.

Authors:  W S Hagler; W H Jarrett; J H Killian
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 Jan-Feb

3.  Kidney graft survival and matching for HL-A and ABO antigens.

Authors:  V C Joysey; J H Roger; D B Evans; B M Herbertson
Journal:  Nature       Date:  1973-11-16       Impact factor: 49.962

4.  Small malignant melanomas of the choroid.

Authors:  F H Davidorf; J R Lang
Journal:  Am J Ophthalmol       Date:  1974-11       Impact factor: 5.258

5.  HL-A and ABO antigens and malignant melanoma. A study of 212 cases.

Authors:  L U Lamm; F Kissmeyer-Nielsen; K E Kjerbye; B Morgensen; N C Petersen
Journal:  Cancer       Date:  1974-05       Impact factor: 6.860

6.  Mlalignant melanomas of the human uvea. Recent follow-up of cases in Denmark, 1943-1952.

Authors:  O A Jensen
Journal:  Acta Ophthalmol (Copenh)       Date:  1970

7.  Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type.

Authors:  H O McDevitt; A Chinitz
Journal:  Science       Date:  1969-03-14       Impact factor: 47.728

Review 8.  Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.

Authors:  L E Zimmerman; I W McLean; W D Foster
Journal:  Br J Ophthalmol       Date:  1978-06       Impact factor: 4.638

9.  Choroidal melanoma. Enucleation or observation? A new approach.

Authors:  W A Manschot; H A van Peperzeel
Journal:  Arch Ophthalmol       Date:  1980-01

10.  Missing evidence for HLA antigen association with Eales' disease, chorioretinitis, central serous retinopathy, and malignant choroidal melanoma.

Authors:  J Bertrams; M Spitznas; M Rommelfanger
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-09       Impact factor: 4.799

View more
  4 in total

1.  The effect of immunological and non-immunological factors on corneal graft survival. A single center study.

Authors:  H J Völker-Dieben
Journal:  Doc Ophthalmol       Date:  1984-04-16       Impact factor: 2.379

2.  Possible relation between HLA and ABO type and prognosis of uveal melanoma.

Authors:  M J Jager; H J Völker-Dieben; D de Wolff-Rouendaal; H Kakebeeke-Kemme; J D'Amaro
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 3.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

Review 4.  Blood biomarkers for uveal melanoma.

Authors:  Pierre L Triozzi; Arun D Singh
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.674

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.